IMMUNIC, INC. Files 8-K for Operations and Financial Condition

Ticker: IMUX · Form: 8-K · Filed: Aug 7, 2025 · CIK: 1280776

Immunic, INC. 8-K Filing Summary
FieldDetail
CompanyImmunic, INC. (IMUX)
Form Type8-K
Filed DateAug 7, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: operations, financial-condition

Related Tickers: IMUX

TL;DR

IMUX filed an 8-K on Aug 7, 2025, for operations/financials. Details TBD.

AI Summary

On August 7, 2025, IMMUNIC, INC. (IMUX) reported its financial results and condition. The filing does not contain specific financial figures or operational details beyond the reporting date.

Why It Matters

This 8-K filing provides an update on IMMUNIC, INC.'s operational and financial status, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting operational and financial condition, with no immediate negative or positive news disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to report on IMMUNIC, INC.'s Results of Operations and Financial Condition as of August 7, 2025.

What is the trading symbol for IMMUNIC, INC. common stock?

The trading symbol for IMMUNIC, INC. common stock is IMUX.

On which exchange is IMMUNIC, INC. common stock registered?

IMMUNIC, INC. common stock is registered on The Nasdaq Stock Market LLC.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is August 7, 2025.

Does this filing provide specific financial results or operational details?

This filing indicates that it is reporting on Results of Operations and Financial Condition, but the specific details are not included in the provided text excerpt.

Filing Stats: 1,129 words · 5 min read · ~4 pages · Grade level 14.1 · Accepted 2025-08-07 06:36:29

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition On August 7, 2025, Immunic, Inc. (the "Company") issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company's financial results for the quarter ended June 30, 2025 and providing a corporate update (the "Press Release"). The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company's filings with the Securities and Exchange Commission (the "SEC"), except as shall be expressly set forth by specific reference in any such filing.

01. Other Events

Item 8.01. Other Events On August 7, 2025, the Company posted an updated presentation (the "Presentation") on its website. A copy of the Presentation is filed herewith as Exhibit 99.2 and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K, the Press Release and the Presentation are "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the Company's development programs and the targeted diseases; the potential for the Company's development programs to safely and effectively target diseases; preclinical and clinical data for the Company development programs; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the Company and further updates with respect thereto; and the development and commercial potential of any product candidates of the Company. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking results and performance c

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits Exhibit Description 99.1 Press Release, dated August 7, 2025. 99.2 Presentation, dated August 7, 2025. 104 Cover Page to this Current Report on Form 8-K in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: August 7, 2025 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing